Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 26, Issue 1, Pages 9-18

Expression of Survivin and Cortactin in Colorectal Adenocarcinoma: Association with Clinicopathological Parameters

Ying-Yu Lee,1 Cheng-Ping Yu,2 Chih-Kung Lin,2 Shin Nieh,2 Kuo-Feng Hsu,1 Hung Chiang,3 and Jong-Shiaw Jin2

1Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
2Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
3Taipei Institute of Pathology, Taipei, Taiwan

Received 20 February 2009; Accepted 20 February 2009

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective: Survivin and cortactin are factors that promote tumor progression. We tested the hypothesis that survivin and cortactin expressions correlate with the clinico-pathological parameters of colorectal adenocarcinomas and survival time. Methods: Immunohistochemical analysis of survivin and cortactin were performed using tissue microarrays of 119 specimens from 18 well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas and 24 colorectal adenomas with dysplasia. As control, 10 specimens of normal colorectal epithelia were included.

Results: The percentage of cells immunostained and the immunostaining scores for survivin and cortactin were all significantly higher in well-, moderately, and poorly differentiated colorectal adenocarcinomas than in normal colorectal epithelia. The survivin immunostaining score was significantly correlated with T, M, and AJCC/TNM stages (p `0.05). For cortactin, the score was significantly correlated with T and M stages (p ` 0.05). Higher survivin immunostaining score was associated with higher mortality.

Conclusions: Higher expression of survivin and cortactin correlates significantly with tumor stages and shorter survival time. Survivin and cortactin may be good biomarkers of aggressiveness of colorectal adenocarcinomas. Our findings require validation in independent cohorts and these data support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies.